vida: extract claims from 2025-xx-pmc-glp1-eating-disorders-double-edged-sword

- Source: inbox/queue/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "Developmental timing creates a double exposure: adolescence is both the peak ED onset period and the demographic with highest social media use driving cosmetic GLP-1 demand"
+confidence: experimental
+source: PMC/Journal of Clinical Medicine systematic narrative review, 2025
+created: 2026-05-04
+title: Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
+agent: vida
+sourced_from: health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
+scope: causal
+sourcer: PMC / Journal of Clinical Medicine
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+---
+
+# Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
+
+The review identifies adolescents as the highest-risk population for GLP-1-induced eating disorder harm through a developmental timing mechanism. Two factors converge: (1) eating disorder prevalence peaks during adolescence, creating a large vulnerable population, and (2) adolescent social media use is highest, maximizing exposure to cosmetic GLP-1 promotion. This creates a compounding risk structure where the population most vulnerable to eating disorder onset is also most exposed to the cultural messaging that drives cosmetic GLP-1 misuse. The review explicitly names adolescents as an at-risk population requiring special consideration, alongside patients obtaining GLP-1s for cosmetic purposes without medical supervision and individuals with prior ED history. This is distinct from general GLP-1 eating disorder risk because it identifies a specific demographic where two independent risk factors (developmental vulnerability + cultural exposure) multiply rather than add.

domains/health/glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal.md

@@ -17,3 +17,10 @@ related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-res
 # No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
 
 This review explicitly confirms that evidence for GLP-1 receptor agonists in anorexia nervosa (AN) is 'extremely limited' with theoretical risks rather than empirical data. The paper states that risks for restrictive eating disorders include 'appetite suppression masking restrictive behaviors, compulsive reliance on medication for control, reinforcement of maladaptive food rules' but provides no RCT citations for these outcomes. This creates a critical evidence gap: pharmacovigilance systems show elevated eating disorder risk (VigiBase aROR 4.17-6.80), clinical guidelines recommend pre-treatment eating disorder screening, yet no prospective trials have tested GLP-1 safety or efficacy in patients with restrictive eating disorder histories. The absence of trial evidence means that current prescribing occurs without subtype-specific risk stratification. The review notes that benefits for BED (reduced binge episodes) 'may not persist long-term,' suggesting that even for the eating disorder subtype with positive theoretical rationale, durability is uncertain. This evidence vacuum is particularly concerning given that the review recommends 'rigorous monitoring until long-term safety in diverse populations established' while acknowledging that such monitoring infrastructure does not currently exist in standard prescribing practice.
+
+
+## Supporting Evidence
+
+**Source:** PMC/Journal of Clinical Medicine systematic review, 2025
+
+Review confirms 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders, while simultaneously documenting case evidence and calling for longer-term follow-up studies (up to 5 years) to detect delayed ED symptom onset.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -17,3 +17,10 @@ related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesoli
 # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
 
 This review establishes that GLP-1 receptor agonists create opposing clinical outcomes across eating disorder subtypes through a single pharmacological mechanism. For binge eating disorder (BED), GLP-1 RAs reduce binge episodes by modulating mesolimbic dopamine circuits that drive reward-based eating. However, for restrictive eating disorders (anorexia nervosa, atypical AN), the same appetite suppression mechanism that benefits BED patients can reinforce existing restriction patterns by enhancing satiety signals in individuals already predisposed to under-eating. The paper notes that evidence for anorexia nervosa is 'extremely limited' with theoretical risks including 'appetite suppression masking restrictive behaviors' and 'reinforcement of maladaptive food rules.' This creates a clinical paradox where the drug's core mechanism of action is therapeutic for one eating disorder subtype and potentially iatrogenic for another. The review identifies highest-risk populations as individuals with restrictive eating disorder histories, those with high perfectionism or OCD traits, adolescents during critical development, and racial/ethnic minorities facing intersectional stigma. This mechanistic framework explains the VigiBase pharmacovigilance signal (aROR 4.17-6.80 for eating disorders) by showing that aggregate eating disorder risk masks subtype-specific directionality.
+
+
+## Extending Evidence
+
+**Source:** PMC/Journal of Clinical Medicine systematic review, 2025
+
+2025 case documented: woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. This provides clinical case evidence for the restrictive ED harm pathway, showing that even medically supervised GLP-1 use can trigger relapse in patients with prior restrictive ED history.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -17,3 +17,10 @@ related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-pe
 # Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
 
 This review provides detailed clinical recommendations for eating disorder risk mitigation: (1) pre-treatment screening using SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation; (2) ongoing monitoring of eating behaviors, mood, and suicidal ideation with heightened vigilance during dose escalations; (3) multidisciplinary approach with psychological care, dietitian, and medical oversight rather than standalone medication; (4) preventive strategies introducing DBT/mindfulness before appetite suppression eliminates food-based coping. However, these recommendations exist only in academic literature. No FDA labeling requirement mandates eating disorder screening before GLP-1 initiation. No professional society guideline (Endocrine Society, Obesity Medicine Association, ADA) requires SCOFF or equivalent screening as a prescribing precondition. The review concludes that GLP-1s 'must be approached with caution: integrated into multidisciplinary care with rigorous monitoring' but this integration is aspirational rather than operationalized. This creates a gap between evidence-based risk mitigation and actual prescribing practice, particularly concerning given that 92 percent of GLP-1 users receive no dietitian support (per existing KB claim) and the review identifies eating disorder history as a primary risk factor requiring specialist oversight.
+
+
+## Supporting Evidence
+
+**Source:** PMC/Journal of Clinical Medicine systematic review, 2025
+
+Review explicitly states 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders specifically, and calls for pre/post-treatment psychological assessment and screening for high-risk ED patients before initiating, but notes these are recommendations not requirements.

domains/health/glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Social media framing of GLP-1s as miracle weight loss enables cosmetic misuse without eating disorder screening, creating predictable harm in restrictive ED-vulnerable populations
+confidence: experimental
+source: PMC/Journal of Clinical Medicine systematic narrative review, 2025
+created: 2026-05-04
+title: GLP-1 social media promotion for cosmetic weight loss creates a novel eating disorder onset pathway in vulnerable populations through unscreened access
+agent: vida
+sourced_from: health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
+scope: causal
+sourcer: PMC / Journal of Clinical Medicine
+supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+---
+
+# GLP-1 social media promotion for cosmetic weight loss creates a novel eating disorder onset pathway in vulnerable populations through unscreened access
+
+The review identifies social media as a mechanism through which GLP-1 misuse reaches eating-disorder-vulnerable populations. Social media promotes GLP-1s 'for esthetic purposes' as miracle weight-loss treatments, which could trigger restrictive eating behaviors in vulnerable individuals. This creates a novel pathway distinct from traditional eating disorder onset: (1) widespread cultural framing of GLP-1s as cosmetic weight loss tools, (2) online access without medical supervision or ED screening, (3) pharmacological appetite suppression that reinforces restrictive patterns in vulnerable users. The review documents a 2025 case where a woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. The review explicitly calls for pre-treatment psychological assessment and screening for high-risk ED patients before initiating GLP-1s, but notes no regulatory requirement exists. This is a structural access governance failure: the same mechanism that makes GLP-1s therapeutically valuable for BED (appetite suppression) becomes harmful for restrictive EDs when deployed without screening infrastructure.

inbox/archive/health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: high
 tags: [glp1, eating-disorders, anorexia, binge-eating, pharmacovigilance, adolescents, misuse]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content